



Top 36-40

09 June 2011 | News





Address: 173- B ,New industrial Estate, Udhna, Surat –

394210, Gujarat

Tel: +91-261-2277211


Fax: +91-261-2279319, 2665757 **Website:** www.span.co.in

Span Diagnostics clocked an estimated revenue of image not found or type unknown 92.53 crore for FY 2010-2011, as against image not found or type unknown 78.98 crore for 2009-10. The company, which has been supplying to India's national programmes for AIDS and malaria since the past eight years, achieved tender sales worth 1/1280 crore from the ype unknown Indian government during the past year. Span currently houses three businesses namely, the diagnostic reagent business, the instruments business and exports, and boasts of a joint venture with Japan-based, Nihon Kohden corporation. The company is looking to modernize its plant by investing 1/12/2/crore over a period of one-and-half years. The company expects to grow at a rate of 17 to 20 percent in 2011, following which, Span anticipates hitting a growth rate of 25 to 30 percent. This confidence is due to the launch of a number of products by 2012 along with an increase in export sales. Span is looking to achieve a turnover of 1900 or or or 2020. unknown

Revenue: In9295316foretnd or type unknown

| Image not found or type | Aventis Pharma |
|--|---|
| | MD Dr Shailesh Ayyangar |
| 37 | Business: Marketing of biotech products |
| | Start-up Year: 1956 |
| Address: Aventis House, 54/A, Sir Mathuradas, Vasanji Road, Andheri East, Mumbai-400093 | |
| Tel: +91-22-28278000 Fax: +91-22-28370939 Website: www.aventispharmaindia.com | |
| Revenue: In9@crore*found or type unknown | |

Aventis Pharma clocked an estimated sales of mage not found or type unknown 90 crore in FY 2010-11 when compared with mage not found or type unknown 68.34 crore in FY 2009-10. The company has consolidated its position in the growing insulin market with its star product Lantus, which has a market share of 10.24 percent, showing a growth of nearly 30 percent. Other insulin brands including Amaryl and Apidra witnessed a growth of 29 percent and 100 percent respectively. During the FY, the company sold off its entire shareholding in the joint venture company, Chiron Behring Vaccines Private to Novartis Pharma for mage not found or type unknown 100.7 crore. The company reduced the price for its monocomponent insulin, Lantus, by 2.8 percent as per the direction from the National Pharmaceutical Pricing Authority (NPPA) from 12,439.27 for a 10 ype unknown ml vial of Lantus 100 IU/ml to 2370.499 Theor type unknown company also has several community service initiatives like the SOS Children's villages, Childline, the Akansha Foundation, Voluntary Health Association of Goa and the Joy of Giving.




Address: Novartis India Limited, Sandoz House, 8th floor, Shivsagar Estate, Dr Annie Besant Road, Worli, Mumbai - 400 018, India

Tel: +91-22-24958804, 24951074

Fax: +91-22-2495 2624 **Website:** www.novartis.in

Revenue: In89:65 crore and or type unknown

In the FY 2010-2011, the vaccine business of Novartis in India clocked 89965 & fore 4n India, unknown Novartis and Aventis Pharma had a 51:49 joint venture in Chiron Behring Vaccines, in which the former had marketing rights of the later's antirabies vaccine, Rabipur, in India. However in December 2010, Aventis Pharma sold off its 49 percent stake in the joint venture to Novartis Vaccines and Diagnostics (NV&D) for around 1000 cror ound or type unknown Novartis Vaccines and Diagnostics division 's portfolio includes some prominent influenza and meningitis vaccines and travel vaccines. In the first half of 2010, the division globally completed the distribution of A(H1N1) vaccine. Now, work has started for developing prepandemic vaccines that would provide protection to the global population against possible future pandemics.



Ajeet Seeds, a producer and processor of hybrid cottonseeds in India, generated a revenue of image not found or type unknown 87.5 crore in 2010-11. The company received approval from the Genetic Engineering Approval Committee (GEAC), Government of India, for the sale of Bollgard I (Ajeet 33, Ajeet 155, Ajeet 177), Ajeet 901 (HxB), ACH 21 (Arya 21 Bt) and Bollgard II (Ajeet-11, Ajeet 155, Ajeet 33), ACH 177 (Arya 177 BG II, Ajeet 111), ACH 5 (Arya 21 BG II) cotton hybrids in Central, South and North zones in 2006.

The company has developed its own genetic resources of hybrid seeds in cotton, jowar, bajra, maize, chilli, okra and pigeon pea. The company has established a wide network of 400 distributors, 3,000 dealers and more than 30,000 seed growers

Address: Tapadia Terraces, 2nd Floor, Adalat Rd,

Aurangabad- 43100

Tel: +91-240-2333933 Fax: +91-240-2333335

Website: www.ajeetseed.co.in

Revenue: In8795 crore und or type unknown

| Image not found or type | Haffkine Bio-Pharmaceutical Corporation |
|--|--|
| | MD Mr P R Sabde |
| 40 | Business: Production and supply of biopharmaceutical products |
| | Start-up Year: 1975 |
| Address: Acharya Donde Marg, Parel, Mumbai - 400012 | |
| Tel: +91-22-24129320 Fax: +91-22-24168578 Website: www.vaccinehaffkine.org | |
| Revenue: In869croré found or type unknown | |

Haffkine Bio-Pharmaceutical Corporation (HBPCL) is engaged in the manufacture and supply of a wide range of products comprising bacterial and viral vaccines, antisera, toxoids injectables, disinfectants, ointments, injectables, syrups and mixtures. The firm clocked an annual sales revenue of 1086 crope from 2010 y 114 against last year's 1168.98 torored The firm's total group turnover, comprising Haffkine Ajintha Pharmaceuticals and Antitoxin and Sera is over mage not found or type unknown 100 crore. The Antitoxin and Sera (ATS) department of HBPCL is located at Pimpri, near Pune, and it is engaged in the manufacture of antiserum against tetanus, diphtheria, gas gangrene, snake and scorpion venoms. The ATS operates on 75 acres of land with a total strength of 400 equines. HBPCL has supplied oral polio vaccines to UNICEF and the Government of India. The company is also planning to build manufacturing facilities complying with the WHO's GMP standards for DTP/pentavalent vaccine.